News about Drug Discovery & Development

Absci Partners with AMD to Propel Future of AI Drug Discovery

AMD will also make a USD 20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery.

Drug Discovery & Development | 10/01/2025 | By Aishwarya |  348

Merck KGaA Adopts Quris-AI's Bio-AI Platform for its Drug Development Pipeline

Quris-AI’s drug safety prediction platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug- induced toxicities better.

Drug Discovery & Development | 09/01/2025 | By Aishwarya |  700

Acellera Rolls Out AceForce 1.0 to Advance Drug Discovery

AceForce 1.0 is a groundbreaking tool in computational chemistry and drug discovery, offering quantum-level accuracy by leveraging a proprietary training set of millions of quantum mechanical (QM) calculations.

Drug Discovery & Development | 08/01/2025 | By Aishwarya |  545

WuXi Biologics Signs Deal with Candid Therapeutics to Boost Trispecific T-cell Engager

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody.

Drug Discovery & Development | 07/01/2025 | By Aishwarya |  537

CSIR Develops Indigenous Tech to Manufacture Paracetamol in India

Karnataka-based Satya Deeptha Pharmaceuticals Ltd will utilize this breakthrough to produce affordable paracetamol domestically.

Drug Discovery & Development | 06/01/2025 | By Aishwarya |  545

Chime Biologics and Mabgeek Complete PPQ for MG-K10

Chime Biologics and Mabgeek's strategic collaboration, first unveiled in 2022, focuses on commercial manufacturing of cGMP 2000L drug substance, late-stage chemistry, manufacturing, and controls (CMC) development and biologics license application (BLA) to accelerate Best-in-Class biologics MG-K10's commercialization.

Drug Discovery & Development | 04/01/2025 | By Aishwarya |  322

ANI Pharmaceuticals Introduces Prucalopride Tablets after FDA Approval

ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity.

Drug Discovery & Development | 03/01/2025 | By Aishwarya |  648

Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan

HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.

Drug Discovery & Development | 31/12/2024 | By Aishwarya |  459

Gerresheimer Announces Tentative Approval of SQ Innovation Lasix ONYU from FDA

Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device.

Drug Discovery & Development | 31/12/2024 | By Aishwarya |  388

Huadong Medicine, SynerK Partners to Jointly Develop Novel siRNA Drug SNK-2726

Huadong Medicine Co., Ltd. and SynerK PharmaTech have partnered to co-develop the siRNA drug SNK-2726, targeting hypertension, with Huadong obtaining exclusive rights for Greater China upon option exercise.

Drug Discovery & Development | 30/12/2024 | By Manvi |  446